🤩 Ha sido todo un honor recibir la beca CRIS de Excelencia dotada con 1.25M€ para diseccionar a un nivel sin precedentes los mecanismos moleculares de los #Sarcomas #GIST - y poder avanzar en el tratamiento de nuestros pacientes 🧬💊 🙏🏼 Muchas gracias a la #CRIScontraelcáncer

This paper from Harvard and MIT quietly answers the most important AI question nobody benchmarks properly: Can LLMs actually discover science, or are they just good at talking about it? The paper is called “Evaluating Large Language Models in Scientific Discovery”, and instead

This article suggests that cancer treatment contributes to mutagenesis: "More than 25% of driver mutations in normal tissue exposed to systemic anti-cancer therapy, including in TP53, could be attributed to treatment."

DART hits the rare cancers target over and over. Nivolumab plus ipilumumab in PECOmas 🎯🎯 https://t.co/c4PlzRtr8x

Happy to share our latest study @Nature , where we evaluate somatic evolution and the effect of treatment in normal tissue using duplex sequencing 1/n https://t.co/fr1Cbj7SDU

Nunca tendré suficientes palabras de agradecimiento para este tipo de iniciativas. La #investigación en #sarcomas la hacemos entre todos 🫂

Congratulations, David Gómez (@dgomezpere)‼️ On defending his thesis: “The genomic landscape of gastrointestinal stromal tumor progression uncovers the role of chromosomal instability in the cytogenetic and clinical evolution of the disease.” 👏 An outstanding achievement driven

👨‍🎓📄 3rd PhD from my #sarcoma lab at @VHIO Congratulations to Dr. David Gómez-Peregrina @dgomezpere 📣 Stay tuned to his terrific computational work on #GIST - sending out soon-ish!

📢📢 Hot off the press: trabectedin+olaparib vs trabectedin in advanced STS just published in @Annals_Oncology‼️ ⚠️Marginal benefit in all comers 🔬🧬Meaningful activity in uLMS and PARP1+ve STS. An outstanding collaboration of the @ItaSarcomaGroup ! https://t.co/ARsVyxL7wi

Germline testing in sarcoma (N=115) 🧩 PGVs in 8.7% → TP53, BRCA1, SDHA, ATM, NBN ⚠️ 70% of PGVs would NOT be detected by current guidelines 📈 Highlights the value of broad-panel germline testing to guide therapy + familial risk assessment 🔗 https://t.co/EK3mNplyeA @OncoAlert

Obituary: Pedro Cuatrecasas (1936–2025) https://t.co/M25A3XhtHI

🥹Siempre me faltará encontrar las palabras suficientes de agradecimiento para familias como la de Fernando, Ozelot, por su compromiso con la ciencia y con la investigación en #sarcomas GRACIAS Su música 🎶👇 Spotify: https://t.co/AftqUHwQCd Apple Music: https://t.co/diZwtBgfIX

In my humble opinion, the next generation of reviews must be more forward-thinking and give personal views on the topic. This would make our works truly unique By the way: everyone shows their concerns with AI, but not with medical writers taking over our duty of writing science

Sensitive and timely call for patient selection and non-reflex NGS testing in patients with sarcoma, applicable to other rare condiditions 🔸Importance of expect centers 🔸Pathology Review 🔸Findings and context by @DrCeSarcoma @jeanyvesblay Dr Sebastien Bauer Link:

OMG 😱 Scientific evidence demonstrate that RT-induced abscopal effect does NOT exist 👇🏼👇🏼👇🏼

Register for the Virtual healthbook CME Webinar - GIST: Moving Toward Tailored Therapies and ctDNA-Guided Decisions, Wednesday, Nov 26, 2025 - 17:00 – 18:25 CET https://t.co/TPcOb5Ohzo #sarcoma #ctDNA #GISTeducation @DrCeSarcoma

🚨Historical presentation at #CTOS2025 ChonDRAgon - first positive randomised trial in chondrosarcoma 🔹Ozekibart vs placebo 🔹 mPFS 5.52 vs 2.66 months 🔹 HR 0.479; p<0.0001 🔹 a manageable safety profile - most common TRAE: fatigue, diarrhea, and nausea

Comenzamos #SEOM25 👇🏼

In this manuscript in @CD_AACR, we investigate target-mediated resistance to ADCs, and propose ways to overcome it. https://t.co/bUSy4zqw1N

Si ya estás preparando la 🧳, no olvides tus 👟👟 Movimiento @_SEOM #EjercicioContraElCancer 🗓️11 a 14 de Noviembre‼️ 📍🏨Meliá Castilla (Madrid) 🚴🏼o🏃‍♀️ y tus Km sumarán💲para una Beca SEOM'26‼️ https://t.co/rALPpWqn0c

We’re thrilled to see positive Phase 3 top-line results from Cogent's PEAK trial of bezuclastinibin combination with sunitinib, the first potential new second-line treatment option for GIST in nearly 20 years. Read their letter to patients here: